Litigation Details for IN RE APPLE INC. SECURITIES LITIGATION (N.D. Cal. 2019)

IN RE APPLE INC. SECURITIES LITIGATION (N.D. Cal. 2019)

Docket	4:19-cv-02033	Date Filed	2019-04-16
Court	District Court, N.D. California	Date Terminated	2024-09-18
Cause	15:78m(a) Securities Exchange Act	Assigned To	Yvonne Gonzalez Rogers
Jury Demand	Plaintiff	Referred To	Joseph Spero
Parties	LUCA MAESTRI
Patents	11,566,011; 11,879,013; 6,667,050; 8,217,007; 9,504,655
Attorneys	Jacob G. Gelman
Firms	Paul, Weiss, Rifkind, Wharton & Garrison LLP
Link to Docket	External link to docket

Details for IN RE APPLE INC. SECURITIES LITIGATION (N.D. Cal. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-04-16				External link to document
2019-04-16	141	Exhibit 5	137,000,000 39.26% 9,504,655 (282,915) Not required to …137,000,000 39.26% 9,504,655 (282,915) Not required to …Corporate legal affairs, legal counseling, litigation, patents, Legal & IPR Center	External link to document

In re Apple Inc. Securities Litigation, 4:19-cv-02033: Case Summary and Analysis

Last updated: August 2, 2026

In re Apple Inc. Securities Litigation is a federal securities class action concerning Apple’s disclosures about iPhone demand in China and other emerging markets. The case arose after Apple disclosed on Jan. 2, 2019, that it would reduce its fiscal first-quarter 2019 revenue guidance, citing weaker-than-expected iPhone sales, particularly in China. The litigation settled for $490 million without an admission of liability.

What is In re Apple Inc. Securities Litigation?

The action was filed in the U.S. District Court for the Northern District of California under Case No. 4:19-cv-02033. The consolidated case was assigned to Judge Yvonne Gonzalez Rogers.

Item	Details
Case	In re Apple Inc. Securities Litigation
Court	U.S. District Court for the Northern District of California
Case number	4:19-cv-02033
Judge	Yvonne Gonzalez Rogers
Defendant	Apple Inc.
Individual defendant	Timothy D. Cook, Apple CEO
Lead plaintiff	Norfolk County Retirement System
Securities involved	Apple common stock
Alleged class period	Nov. 2, 2018, through Jan. 2, 2019
Core allegation	Apple allegedly misled investors about weakening iPhone demand in China
Settlement amount	$490 million
Liability admission	None

The plaintiffs alleged that Apple and Cook violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.

What triggered the Apple securities lawsuit?

The case followed Apple’s Jan. 2, 2019, letter to investors revising its fiscal first-quarter 2019 revenue guidance downward. Apple reduced its expected revenue from a range of approximately $89 billion to $93 billion to approximately $84 billion.

Apple attributed the revision primarily to lower-than-expected revenue in Greater China and other emerging markets. The company cited several factors, including:

• Lower iPhone sales than Apple had anticipated.
• A stronger U.S. dollar.
• Fewer carrier subsidies.
• Customers responding to lower prices for battery replacements.
• Consumers delaying purchases because of longer iPhone replacement cycles.
• Macroeconomic weakness in China.

The disclosure caused Apple’s share price to fall. Plaintiffs contended that the market had been misled before the guidance revision because Cook had publicly described Apple’s business in China in favorable terms while allegedly withholding information about deteriorating iPhone demand.

What statements formed the basis of the claims?

The claims focused heavily on Cook’s Nov. 1, 2018, earnings-call remarks. Cook discussed Apple’s performance in emerging markets and said the company had seen pressure in some markets, including Brazil, India, Russia and Turkey, but characterized China as a different situation.

According to the amended complaint, Cook stated that Apple had a strong position in China and that its business there was not being affected in the same manner as certain other emerging markets. Plaintiffs alleged that the statements were materially misleading because Apple allegedly knew that iPhone demand in China was weakening.

The theory was not that Apple had to disclose every internal sales trend. The central question was whether Apple’s public statements created a materially misleading impression by omitting known information about deteriorating demand.

What did the plaintiffs allege against Apple and Tim Cook?

The plaintiffs’ allegations had four principal components.

Alleged knowledge of declining iPhone demand

Plaintiffs alleged that Apple had access to internal sales data showing weakness in iPhone demand in China before the Nov. 1 earnings call.

Alleged misleading statements about China

The complaint asserted that Cook’s statements distinguished China from other weak emerging markets and caused investors to believe that Apple’s China business remained comparatively strong.

Alleged omission of adverse information

Plaintiffs argued that Apple failed to disclose that iPhone sales in China had deteriorated materially and that the company was experiencing increasing pressure from local competitors, including Huawei.

Alleged corrective disclosure

The Jan. 2, 2019, revenue-guidance reduction allegedly revealed the truth to the market and caused investor losses.

The plaintiffs sought damages for investors who purchased Apple stock during the proposed class period.

How did Apple defend the case?

Apple denied that its public disclosures were false or misleading. Its defenses included the following:

• Cook’s statements were corporate opinions or generalized business commentary rather than actionable misrepresentations.
• Apple’s disclosures adequately warned investors that its business was subject to market, currency, macroeconomic and product-demand risks.
• The challenged statements were protected by the Securities Litigation Uniform Standards Act safe harbor for forward-looking statements.
• The complaint did not establish that Cook acted with the required fraudulent intent.
• The plaintiffs had not adequately connected the alleged statements to the later stock-price decline.
• Apple’s Jan. 2 disclosure reflected changing market conditions and management judgment rather than the revelation of previously concealed facts.

The scienter issue was central. Under the Private Securities Litigation Reform Act, plaintiffs in a federal securities case must plead particularized facts supporting a strong inference that the defendants acted with fraudulent intent or severe recklessness.

What was the procedural history?

The case proceeded through consolidation, appointment of a lead plaintiff, motions to dismiss and amended pleadings.

Date	Event
2019	Securities complaints were filed following Apple’s Jan. 2 revenue-guidance revision.
2019	Related actions were consolidated in the Northern District of California.
2019	Norfolk County Retirement System was appointed lead plaintiff.
2020-2023	The parties litigated the sufficiency of the amended complaint and exchanged discovery.
March 2024	Apple agreed to a $490 million settlement.
2024	The court conducted the settlement-approval process and established procedures for class-member notice and claims administration.

The settlement resolved the claims without a judicial finding that Apple violated the securities laws.

Was the Apple case dismissed or settled?

The case was settled, not resolved through a trial verdict. Apple agreed to pay $490 million to settle the investor claims.

The settlement covered investors who purchased Apple common stock during the specified class period, generally from Nov. 2, 2018, through Jan. 2, 2019. The settlement agreement released claims arising from the alleged misstatements and omissions concerning Apple’s China business and iPhone demand.

Apple denied wrongdoing and did not admit liability as part of the settlement.

What was the financial exposure for Apple?

The $490 million settlement was a significant securities-litigation payment but modest relative to Apple’s cash resources and annual revenue.

The payment represented:

• Direct settlement consideration of $490 million.
• Potential deductions for attorneys’ fees, litigation expenses and administrative costs.
• Distribution to eligible class members under a court-approved allocation formula.
• No requirement for Apple to restate its financial statements.
• No injunction requiring changes to Apple’s disclosure practices.
• No criminal or regulatory penalty.

The case therefore created a financial cost and disclosure-related litigation risk but did not impose an operational restriction on Apple’s products, pricing or reporting systems.

What legal issues determined the settlement value?

Materiality

The plaintiffs needed to show that the challenged statements would have mattered to a reasonable investor. China was a major market for Apple, and the alleged weakness concerned the company’s principal product, the iPhone.

Scienter

The plaintiffs needed to establish a strong inference that Cook and Apple knew, or recklessly disregarded, that their statements about China were misleading. Internal sales data, management communications and the timing of the Jan. 2 guidance reduction were important to this issue.

Loss causation

The plaintiffs had to show that the alleged corrective disclosure caused the economic loss. Apple’s position was that the stock-price decline could also have reflected macroeconomic conditions, currency movements, broader technology-sector weakness and changing expectations about iPhone demand.

Omissions versus affirmative misstatements

The case illustrates the distinction between a company’s duty to disclose material information and its duty not to create a misleading impression through selective statements. A company generally does not have to disclose every unfavorable internal development. The risk increases when management makes specific statements that allegedly contradict known operating conditions.

Forward-looking statement protection

Apple’s public guidance and risk disclosures raised questions about whether certain challenged statements were protected by the statutory safe harbor. The protection is limited when a statement is not genuinely forward-looking, lacks meaningful cautionary language or is made with actual knowledge of falsity.

How strong was the plaintiffs’ case?

The case had meaningful litigation risk for Apple but also presented substantial proof challenges for the investors.

Factors supporting the plaintiffs

• Apple’s Jan. 2 guidance reduction was closely tied to weaker-than-expected China revenue.
• The alleged class period was short and focused on a discrete set of public statements.
• China was commercially significant to Apple.
• The timing between the Nov. 1 earnings call and Jan. 2 guidance revision supported an inference that relevant information may have been available before the call.
• The alleged corrective disclosure involved a company-issued revenue revision rather than an outside analyst report.

Factors supporting Apple

• Apple had disclosed broad risks involving China, foreign exchange, macroeconomic conditions and product demand.
• Statements about market strength can be difficult to prove false unless plaintiffs identify a specific contradictory fact.
• The stock-price decline could have resulted from multiple causes.
• Securities plaintiffs faced a demanding scienter standard.
• Apple could argue that management’s Nov. 1 statements reflected its assessment at that time rather than a guarantee of future performance.

The $490 million settlement indicates that both sides faced material litigation risk. It does not establish the probability that plaintiffs would have prevailed at trial.

What was the regulatory significance of the case?

The case was private securities litigation, not an FDA, SEC enforcement or product-liability proceeding.

Regulatory area	Effect of the case
FDA approval	None
Product authorization	None
SEC enforcement action	No SEC enforcement judgment was part of the settlement
Financial restatement	None reported as a settlement requirement
Exchange Act liability	Alleged by plaintiffs, not established by trial judgment
Corporate disclosure controls	No public injunction requiring specific reforms
Consumer product regulation	No direct effect

The case nonetheless had SEC-law implications because it addressed the accuracy of public-company disclosures, management commentary and revenue guidance.

What were the settlement terms?

The core settlement terms were:

1. Apple paid $490 million into a settlement fund.
2. The settlement resolved claims against Apple and Cook arising from the alleged disclosures during the class period.
3. Apple denied wrongdoing and liability.
4. Eligible investors could submit claims under the court-approved claims process.
5. The court determined the procedures for notice, administration, fee requests and final distribution.
6. Class counsel sought court approval for attorneys’ fees and reimbursement of litigation expenses.

Settlement recoveries depended on each claimant’s recognized loss and the total number of valid claims. The gross settlement amount did not equal the amount each investor received.

What generic entry, biosimilar and patent issues apply?

No generic-entry, biosimilar, Orange Book, formulation-patent or method-of-use issue applies to this case. It concerns investor disclosures about Apple’s commercial performance, not a pharmaceutical product or intellectual-property estate.

How does this case compare with product-liability litigation against Apple?

The case differs from product-liability actions in several ways:

Issue	Securities litigation	Product-liability litigation
Protected interest	Investment value	Personal injury or property damage
Governing law	Federal securities statutes	State tort and product laws
Central proof issue	Material misstatement, scienter and loss causation	Defect, causation and injury
Remedy	Investor damages	Compensatory and, in some cases, punitive damages
Regulatory focus	Public-company disclosure	Product safety and compliance
Class structure	Purchaser class during a defined trading period	Often injury-specific and fact-specific
Typical evidence	Earnings calls, filings, internal sales data and stock-price analysis	Product testing, engineering records and medical evidence

What is the business impact of the Apple settlement?

The direct financial impact was limited compared with Apple’s overall scale, but the case created several business consequences:

• Increased scrutiny of Apple’s regional sales disclosures.
• Greater litigation sensitivity around CEO commentary on China and emerging markets.
• Potential pressure to align earnings-call statements more closely with internal demand indicators.
• Continued exposure to shareholder claims when a later guidance revision appears to contradict earlier management statements.
• A precedent for investor plaintiffs seeking large recoveries from companies with concentrated exposure to China or other volatile markets.

The principal risk was disclosure-related rather than product-related. The case did not restrict Apple’s ability to sell iPhones, modify prices, change its distribution strategy or launch new products.

What is the current litigation status?

The litigation was resolved through the $490 million settlement rather than a merits trial. The settlement process included court review, class notice and claims administration. The settlement did not constitute an admission that Apple or Cook violated the Exchange Act.

For legal and financial analysis, the case should be treated as a closed securities action subject to the terms of the court-approved settlement and any remaining administrative procedures.

Key Takeaways

• In re Apple Inc. Securities Litigation, 4:19-cv-02033, involved alleged misstatements about iPhone demand in China.
• The alleged class period ran from Nov. 2, 2018, through Jan. 2, 2019.
• The claims focused on Tim Cook’s Nov. 1, 2018, earnings-call comments and Apple’s Jan. 2, 2019, revenue-guidance reduction.
• Apple agreed to pay $490 million to settle the case.
• Apple denied wrongdoing and made no admission of liability.
• The case did not involve FDA regulation, patents, generic drugs, biosimilars or product authorization.
• The principal legal issues were materiality, scienter, loss causation, omissions and forward-looking-statement protection.
• The settlement resolved the investor claims without a trial verdict, injunction or required financial restatement.

Frequently Asked Questions

Who was the lead plaintiff in In re Apple Inc. Securities Litigation?

Norfolk County Retirement System was appointed lead plaintiff in the consolidated securities action.

Which Apple stock purchases were covered by the settlement?

The settlement generally covered purchases of Apple common stock from Nov. 2, 2018, through Jan. 2, 2019, subject to the court-approved settlement definition and claim requirements.

Did Tim Cook personally admit securities fraud?

No. The settlement included no admission of wrongdoing or liability by Tim Cook or Apple.

Why was China central to the Apple securities case?

China was a major iPhone market, and the plaintiffs alleged that Apple’s public comments portrayed the China business as stronger than internal conditions supported before the company reduced its revenue guidance.

Did the settlement require Apple to change its financial reporting?

No public settlement term required Apple to restate financial statements or implement a specific disclosure-control program.

References

1. Apple Inc. (2019, January 2). Letter to investors. Apple Investor Relations.

2. In re Apple Inc. Securities Litigation, No. 4:19-cv-02033-YGR, U.S. District Court for the Northern District of California.

3. Securities Exchange Act of 1934, §§ 10(b), 20(a), 15 U.S.C. §§ 78j(b), 78t(a).

4. Securities and Exchange Commission. (2005). Commission guidance regarding management’s discussion and analysis of financial condition and results of operations. Release No. 33-8350.

5. Reuters. (2024, March 15). Apple agrees to pay $490 million to settle lawsuit over China sales comments. Reuters.